Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN Biotech Investing
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia Biotech Investing
"LEQEMBI®" IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China Biotech Investing
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia Biotech Investing
ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs Biotech Investing
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS Biotech Investing
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Biotech Investing
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy Biotech Investing
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations Biotech Investing
